Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Eur J Cardiothorac Surg. 2023 Apr 3;63(4). doi: 10.1093/ejcts/ezad072.
Haemorrhagic and thrombotic complications are known obstacles in extracorporeal life support (ECLS), and patients requiring post-cardiotomy (PC)-ECLS are particularly prone. The objective of this study was to characterize the incidence, type and clinical relevance of bleeding and thrombotic events in patients on PC-ECLS.
A total of 504 patients receiving PC-ECLS between 2000 and 2021 at a single centre were included in a retrospective analysis. Incidence and type of haemorrhagic and thrombotic complications in patients on PC-ECLS were assessed. Overall survival was compared, and perioperative risk factors for bleeding and thrombotic events were assessed by binary logistic regression.
Of the 504 patients requiring PC-ECLS, 196 patients (38.9%) had 235 bleeding events [surgical site: n = 135 (26.8%); cannulation site: n = 68(13.4%); requiring surgical revision: n = 39 (7.7%); cannulation site change: n = 17 (3.4%); fatal cannulation site bleeding: n = 4(0.8%); intracranial haemorrhage: n = 11 (2.1%); gastrointestinal haemorrhage: n = 8 (1.6%); pulmonary haemorrhage: n = 8 (1.6%); and intra-abdominal/retroperitoneal haemorrhage: n = 5 (1%)]. Overall mortality was higher in patients with major bleeding complications than in patients without bleeding complications (P < 0.0001).A total of 74 patients (14.7%) had 84 thrombotic events [ischaemic stroke, n = 39 (7.7%); cannula/circuit thrombosis, n = 26 (5.2%); peripheral embolism, n = 11 (2.2%); device exchange for haemolysis, n = 8 (1.6%)]. Another 246 patients (48.8%) had at least 1 haemocompatibility-related adverse event. Preoperative dual antiplatelet therapy [adjusted odds ratio (OR): 1.83, 95% confidence interval (CI): 1.063-3.137] and ECLS duration (adjusted OR: 1.14, 95% CI: 1.086-1.197) were identified as independent risk factors for haemorrhage. Prior stroke/transient ischaemic attack (adjusted OR: 1.91, 95% CI: 1.08-3.83) and ECLS duration (adjusted OR: 1.09, 95% CI: 1.04-1.15) were identified as risk factors for thrombotic events.
Bleeding complications in patients on ECLS are common and significantly impair survival. Nearly half of the patients were affected by any haemocompatibility-related event.
出血和血栓并发症是体外生命支持(ECLS)中已知的障碍,而需要心脏手术后(PC)-ECLS 的患者尤其容易发生。本研究的目的是描述接受 PC-ECLS 的患者出血和血栓事件的发生率、类型和临床相关性。
在一家中心对 2000 年至 2021 年间接受 PC-ECLS 的 504 例患者进行了回顾性分析。评估 PC-ECLS 患者的出血和血栓并发症的发生率和类型。通过二元逻辑回归评估整体存活率,并评估围手术期出血和血栓事件的风险因素。
在需要 PC-ECLS 的 504 例患者中,196 例患者(38.9%)发生 235 次出血事件[手术部位:n=135(26.8%);插管部位:n=68(13.4%);需要手术修正:n=39(7.7%);插管部位改变:n=17(3.4%);致命插管部位出血:n=4(0.8%);颅内出血:n=11(2.1%);胃肠道出血:n=8(1.6%);肺出血:n=8(1.6%);和腹腔/腹膜后出血:n=5(1%)]。与无出血并发症的患者相比,有大出血并发症的患者死亡率更高(P<0.0001)。74 例患者(14.7%)发生 84 次血栓事件[缺血性脑卒中,n=39(7.7%);导管/回路血栓形成,n=26(5.2%);外周栓塞,n=11(2.2%);因溶血而更换设备,n=8(1.6%)]。另有 246 例患者(48.8%)至少发生 1 次与血液相容性相关的不良事件。术前双联抗血小板治疗(调整后的优势比[OR]:1.83,95%置信区间[CI]:1.063-3.137)和 ECLS 持续时间(调整后的 OR:1.14,95% CI:1.086-1.197)被确定为出血的独立危险因素。既往卒中/短暂性脑缺血发作(调整后的 OR:1.91,95% CI:1.08-3.83)和 ECLS 持续时间(调整后的 OR:1.09,95% CI:1.04-1.15)被确定为血栓事件的危险因素。
ECLS 患者的出血并发症很常见,严重影响生存率。近一半的患者受到任何与血液相容性相关的事件的影响。